Latest Biotech News

Corxel Pharmaceuticals closed a $287 million Series D1 financing to advance CX11, an oral small‑molecule GLP‑1 receptor agonist for obesity and type 2 diabetes. Investors included RTW Investments,...

Sarepta released three‑year follow‑up data for Elevidys (delandistrogene moxeparvovec) suggesting durable functional benefits versus external historical controls. Company analyses show widening...

Two parallel forces are reshaping U.S. drug pricing: litigation against the Inflation Reduction Act’s price controls and fresh White House policy proposals targeting insurers. Multiple drugmakers,...

Diasorin signed an exclusive U.S. distribution agreement with Fisher Scientific (Thermo Fisher) to place its Liaison NES rapid point‑of‑care qPCR system into hospitals. The device received FDA...

Catalent plans to close its Gosselies, Belgium cell‑therapy facility, citing changing market dynamics and customer needs. The move raises questions about capacity and access for cell therapy...

Genmab stopped enrollment in an early‑stage Phase 1/2 study of GEN1286, a cancer candidate acquired through its $1.8 billion buyout of ProfoundBio. The study had targeted roughly 260 patients; the...

Sarepta Therapeutics released longer-term data showing durable effects three years after treatment with its Duchenne muscular dystrophy (DMD) gene therapy. The company presented findings from its...

Diasorin signed an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific, to place its Liaison NES rapid point-of-care qPCR system into U.S. hospital channels....

Genmab paused patient enrollment in an early‑stage trial of GEN1286, an oncology candidate acquired through its $1.8 billion purchase of ProfoundBio. The Phase 1/2 study had been planned to enroll...

Insilico Medicine Cayman Topco announced FDA clearance of an investigational new drug (IND) application for ISM‑8969, enabling initiation of a Phase I trial in healthy volunteers for a Parkinson’s...

Fortitude Biomedicines closed a $13 million seed round to develop GLUE‑DACs—antibody‑drug conjugates that use molecular glue degraders as payloads—and advance a lead preclinical immune‑cell...

Corxel Pharmaceuticals closed a $287 million Series D1 financing to accelerate global development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The...

Qiagen is reportedly assessing strategic options, including a potential sale, according to a Bloomberg report that sent shares higher. The life‑science tools and diagnostics provider has held...

A Phase I study reported that natural killer (NK) cell infusions produced promising signals in patients with recurrent hepatocellular carcinoma after liver transplantation. Investigators led by...

Worldwide Clinical Trials, a Kohlberg‑backed contract research organization, agreed to acquire Catalyst Clinical Research, a private CRO with oncology expertise. The deal is another example of...

Biotech investor Cormorant Capital raised $150 million to back another blank‑check merger as SPAC activity rebounds in life sciences. The firm, known for prior crossover SPAC deals with Moonlake...

Corxel Pharmaceuticals closed a $287 million Series D1 round to accelerate global development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The...

Genmab halted patient enrollment in a Phase 1/2 trial of GEN1286, a cancer candidate acquired through its $1.8 billion purchase of ProfoundBio. The pause affects a study originally planned to...

Cigna’s Express Scripts is reportedly in discussions to settle claims by the Federal Trade Commission that pharmacy benefit managers steered patients to higher‑priced insulin to capture rebates....

Qiagen is reported to be evaluating strategic options, including possible sale discussions with multiple potential buyers, according to market reports. The life‑science tools and diagnostics...